StockData

NextCure, Inc. (NXTC) income statement

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.88+0.18 (+2.76%)

Close on Nov 18, 2026Market cap $31.52MP/E –Yield 0.00%

NextCure, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
-111.2%

Financial strength

Current ratio
3.47
Debt to equity
–
Debt to assets
–
Cash to current liabilities
238.0%

Valuation

P/E ratio
–
Price to sales
–
Price to book
2.59
Dividend yield
0.00%

See a number that looks wrong?